Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease
- 5 October 2012
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Drug Delivery
- Vol. 9 (11), 1393-1407
- https://doi.org/10.1517/17425247.2012.730517
Abstract
Inflammatory bowel disease (IBD) is a chronic relapsing idiopathic disease. In clinical terms, most patients require lifelong medication associated with possible unpleasant adverse effects. Oral colon-specific drug delivery systems are designed to deliver therapeutic drugs to the inflamed colon to target pathophysiological manifestations of IBD. The aim is to maintain the drug with proper concentration in the inflamed colon, to enhance drug residence time and to minimize drug absorption by healthy tissues. This review addresses the main barriers for colon-specific drug delivery from organism, tissue and cell levels, respectively. It also summarizes novel colon-specific therapeutic strategies using microparticles and nanoparticles. Oral colon-specific drug delivery represents a possible approach toward efficient treatment of IBD. As the environment of the gastrointestinal tract is harsh and intricate, this approach requires that drug carriers can respond to specific environmental factors of the inflamed colon, permitting stimulus-responsive release of loaded drugs to specific cells or even into specific organelles within cells.Keywords
This publication has 101 references indexed in Scilit:
- Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriersAdvanced Drug Delivery Reviews, 2011
- Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitisInflammatory Bowel Diseases, 2011
- Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel DiseaseClinical and Translational Gastroenterology, 2011
- Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel diseaseJournal of Controlled Release, 2011
- Functional TNFα gene silencing mediated by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colonBiomaterials, 2010
- Orally delivered thioketal nanoparticles loaded with TNF-α–siRNA target inflammation and inhibit gene expression in the intestinesNature Materials, 2010
- Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissuesAdvanced Drug Delivery Reviews, 2008
- Addressing the PEG Mucoadhesivity Paradox to Engineer Nanoparticles that “Slip” through the Human Mucus BarrierAngewandte Chemie-International Edition, 2008
- Role of HIF-1 and NF-κB Transcription Factors in the Modulation of Transferrin Receptor by Inflammatory and Anti-inflammatory SignalsJournal of Biological Chemistry, 2008
- Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory TargetScience, 2008